Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,338 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05178472Recruiting
Spine radiation plus cement procedure for spine metastasis
This study looks at whether treating certain spine tumors with a cement procedure (vertebroplasty) plus focused radiation can control the cancer and improve quality of life. It is for adults with spine metastases that are not clearly defined and meet specific stability and imaging needs.
Columbus, OhioAges 18 years+ - NCT04947254RecruitingPhase 2
Add niraparib to hormone therapy after prostate radiation
This Phase 2 trial tests whether adding niraparib to standard hormone therapy (androgen ablation) after radiation works better for men with high-risk, localized or locally advanced prostate cancer. It may help control the cancer for longer, while also collecting extra tissue and blood to study why the treatment works or doesn’t.
Houston, TexasAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT04222062RecruitingPhase 2
Compare Gliadel implant versus focused brain radiation
This Phase 2 study compares two ways to treat brain metastases: a Gliadel wafer placed during planned surgery versus focused stereotactic radiosurgery. It aims to see which approach works better and is safer for people with a limited number of brain tumor spots.
Detroit, MichiganAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT03184038Recruiting
Testing brain function in people with brain metastases after radiosurgery
This study looks at how well your thinking and memory work after treatment with radiosurgery for brain metastases. It may help researchers understand which patients benefit best and how to monitor side effects on brain function.
Sewell, New JerseyAges 18 years+ - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT00900497Enrolling by invitationPhase 1/Phase 2
Donor white blood cells to treat solid tumors
This Phase 1/2 study tests whether donated white blood cells (granulocytes) from healthy donors can help treat solid cancers that cannot be cured or have stopped responding to standard treatments. The goal is to see safety first, and then whether the treatment can shrink or control tumors.
Boynton Beach, FloridaAges 18 years+ - NCT07344779Recruiting
Darolutamide with hormone therapy for advanced prostate cancer
This study looks at how well the drug darolutamide works when combined with hormone therapy, with or without chemotherapy, for men whose prostate cancer has spread. It aims to see how effective this treatment is in everyday medical practice, not just in a research lab.
Many LocationsAges 18 years+ - NCT07880600Recruiting
MRI-based model to predict chemotherapy benefit for triple-negative breast cancer
This trial uses a special MRI-based computer model to predict how well chemotherapy will work before surgery for triple-negative breast cancer. It aims to help doctors tailor treatment to each patient's likely response.
Fuzhou, FujianAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Anchorage, AlaskaAges 18 years+ - NCT07700758RecruitingPhase 2
Belzutifan for teenagers with solid tumors
This study tests an oral drug called belzutifan in teenagers with certain solid tumors. Belzutifan may shrink tumors by blocking a protein that helps them grow.
Iowa City, IowaAges 12–17 - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Birmingham, AlabamaAges 18 years+ - NCT07448142RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo for advanced rectal cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called pucotenlimab, and chemotherapy for locally advanced rectal cancer that has not spread. The goal is to see if adding radiation helps shrink the tumor more effectively before surgery.
Guangzhou, GuanggongAges 18–75 - NCT03671252RecruitingPhase 3
Chemotherapy before surgery for rectal cancer vs chemo with radiation
This Phase 3 trial compares two treatment plans given before rectal surgery. It tests whether stronger chemotherapy alone works better than chemotherapy pills plus long-term radiation to improve outcomes for locally advanced rectal cancer.
Guangzhou, GuangdongAges 18–75 - NCT03961373RecruitingPhase 3
Standard vs longer lymph node surgery after chemo for stomach cancer
This study compares two surgical approaches to remove lymph nodes after you’ve already had chemotherapy for stomach cancer. It aims to see whether removing lymph nodes in a more extended way improves outcomes without causing unacceptable side effects.
SienaAges 18–80 - NCT03825861RecruitingPhase 2
Before-surgery chemotherapy for locally advanced stomach cancer
This Phase 2 study tests chemotherapy given before surgery (called FOLFIRINOX) for people with locally advanced stomach cancer. The goal is to shrink the tumor and improve outcomes after the surgery plan is completed.
São PauloAges 18–75 - NCT04733820RecruitingPhase 3
Extra chemo after surgery for advanced cervical cancer
This Phase 3 trial tests whether adding chemotherapy after surgery helps people with locally advanced cervical cancer, especially when prior treatment didn’t fully match standard guidelines. It looks at whether this “adjuvant” chemotherapy improves outcomes after neoadjuvant chemotherapy and an extensive hysterectomy.
Wuhan, HubeiAges 18–70 - NCT05148767RecruitingPhase 4
UGT1A1-guided irinotecan for locally advanced rectal cancer
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Hangzhou, ZhejiangAges 18–75 - NCT05172310RecruitingPhase 1
PET scan study using a new tracer for solid tumors
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
StockholmAges 19 years+ - NCT04974346RecruitingPhase 3
Radiation to prevent spread in cervical cancer lymph nodes
This Phase 3 trial tests whether adding a preventive radiation treatment to lymph node areas near the abdomen helps stop cervical cancer from spreading. It aims to improve outcomes for people with certain cervical cancer stages and lymph node results on PET-CT.
Hangzhou, ZhejiangAges 18–75 - NCT05201430RecruitingPhase 3
FOLFOXIRI vs CapeOX before surgery for locally advanced rectal cancer
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,338 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.